Since rituximab targeting CD20 was first approved for Non-Hodgkin’s lymphoma (NHL) in 1997, the US Food and Drug Administration (FDA) has approved a variety of therapeutic monoclonal antibodies, which can target CD19, HER-2, VEGFA, EGFR, and CD52, etc. (Table 1). The gene discussed is CD52; the disease is non-Hodgkin lymphoma.